Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis was written by Avivi, Irit;Perry, Chava;Segman, Yafit;Amit, Odelia;Bar-On, Yaeli;Katz, Ofrat Beyer;Gold, Ronit;Ribakovsky, Elena;Avigdor, Abraham;Vainstein, Vladimir;Goldschmidt, Neta;Ringelstein-Harlev, Shimrit;Horowitz, Netanel A.;Gutwein, Odit;Gurion, Ronit;Itchaki, Gilad;Abadi, Uri;Nemets, Anatoly;Sofer, Orit;Vezker, Miri;Tadmor, Tamar;Dally, Najib;Filanovsky, Kalman;Leiba, Merav;Sarid, Nadav;Benyamini, Noam;Luttwak, Efrat;Herishanu, Yair;Ram, Ron. And the article was included in Annals of Hematology in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:
Polatuzumab (Pola)-based regimens and chimeric antigen receptor T (CAR T) cells provide superior outcome compared to conventional chemoimmunotherapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). Choosing between these strategies remains controversial. The efficacy of CAR T vs. Pola-rituximab(R) /Pola-bendamustine(B)-R in R/R DLBCL patients after failing ≥2 lines of treatment was compared in a retrospective, ‘real-world’ study. Propensity score matching, for age, lymphoma category (de-novo/transformed), number of prior lines, Eastern Cooperative Oncol. Group performance status and lactate dehydrogenase level, was applied to control for differences in patients’ characteristics. Response rate, progression-free survival (PFS) and overall survival (OS) were analyzed. A total of 82 patients, treated with CAR T (n = 41) or Pola-based regimens (n = 41), were included. No treatment-related deaths occurred with CAR T vs. 3 (7.3%) with Pola. The overall and complete response rates were 83% and 58% with CAR T vs. 66% and 44% with Pola-based-regimens (p = 0.077 and p = 0.18, resp.). At a median follow-up of 9 mo (range 1-19.2) and 16 mo (range 0.7-25.3) for the CAR T and Pola arm resp., the median PFS has not been reached for CAR T vs. 5.6 mo for Pola (95% CI 3.6-7.6, p = 0.014). Median OS has not been reached for CAR T vs. 10.8 mo (95% CI 2.2-19.4) for Pola (p = 0.026). To conclude, in a real-world setting, treatment with CAR T achieved superior PFS and OS compared to Pola-based regimens in patients with R/R DLBCL. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Product Details of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem